Plain-English translation of NCT06993636 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Kawasaki Disease research guide →This trial is studying how a blood thinner called rivaroxaban works in children aged 2 to 18 who have developed enlarged coronary arteries (the blood vessels that supply the heart) as a complication of Kawasaki disease. The research team will measure how much of the medication is in your child's bloodstream and how well it's preventing blood clots, using blood tests and heart imaging. This information will help doctors figure out the best dose of this treatment for children with this specific heart condition.
Kawasaki disease can cause serious long-term damage to the heart's blood vessels, and children with enlarged coronary arteries need blood-thinning medication to prevent dangerous clots. However, there isn't much information about how this particular medication works in children, so this study aims to gather that crucial data to guide safer and more effective treatment.
You likely qualify if…
You likely don't qualify if…
Your child will continue taking the blood thinner medication as prescribed by their doctor, but the research team will collect additional blood samples to measure medication levels and how well it's working. You'll share your child's medical information and records from their existing Kawasaki disease care, and the doctors will monitor your child's progress through regular visits over several months. The study is observational, meaning the researchers are watching and measuring rather than changing your child's treatment plan.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
China
Sponsor
Children's Hospital of Fudan University
Enrollment target
~60 participants
Started
January 2023
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
2 Years – 18 Years
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Fang Liu, MD
Children's Hospital of Fudan University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.